

Product Data Sheet

Product Name: SB408124

Cat. No.: GC15317

Chemical Properties

Cas. No. 288150-92-5

Chemical Name 1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea

SMILES CC1=NC2=C(C=C(C=C2C(=C1)NC(=O)NC3=CC=C(C=C3)N(C)C)F)F


Formula C₁₉H₁₈F₂N₄O M.Wt 356.38

Solubility ≥ 35.4 mg/mL in DMSO with gentle warming, ≥ 1.76 mg/mL in EtOH with ultrasonic and warming Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

SB408124 is a potent and novel nonpeptide antagonist of orexin-1 (OX(1)) receptor with K_i values of 27 nM and 57 nM in membrane formats and in whole cell, respectively. SB408124 was 50-fold

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

selective over the human OX2 receptor [1].

Pre-treated with SB408124 before orexin A in primary astrocyte cultures from the rat cerebral cortex remarkably decreased the orexin A stimulatory activity on forskolin and basal-induced cAMP production [2].

In rats, SB408124 at dose of 30 µg/10 µl together with orexin-A after histamine (HA) or hypertonic saline injection could prevent the orexin-A-induced reduction in vasopressin (VP) concentration increase [3].

References:

[1] Langmead CJ1, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ.Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol. 2004 Jan;141(2):340-6.

[2] Woldan-Tambor A1, Biegańska K, Wiktorowska-Owczarek A, Zawilska JB. Activation of orexin/hypocretin type 1 receptors stimulates cAMP synthesis in primary cultures of rat astrocytes. Pharmacol Rep. 2011;63(3):717-23.

[3] Kis GK1, Molnár AH, Daruka L, Gardi J, Rákosi K, László F, László FA, Varga C.The osmotically and histamine-induced enhancement of the plasma vasopressin level is diminished by intracerebroventricularly administered orexin in rats. Pflugers Arch. 2012 Apr;463(4):531-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA